Physician profile
Arturo Castro
NPI 1427052901
$3,025.96
in general payments reported to CMS, 2019-2025
28 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $830 · 2021: $1,031 · 2022: $337 · 2023: $99.34 · 2024: $204 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,270.24 | 2020-2022 | |
| Novo Nordisk INC | $276.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Genzyme Corporation | $245.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.56 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $159.42 | 2019-2022 | |
| Lilly USA, LLC | $93.90 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $85.69 | 2022-2024 | |
| Rhythm Pharmaceuticals, INC. | $84.47 | 2024 | Imcivree |
| Xeris Pharmaceuticals, INC. | $60.13 | 2020-2022 | |
| Abbvie INC. | $56.13 | 2019-2024 | |
| Corcept Therapeutics | $45.96 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $45.32 | 2020 | |
| Tandem Diabetes Care, INC. | $42.65 | 2020 | |
| Amarin Pharma, INC. | $41.04 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $36.53 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $28.29 | 2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $24.71 | 2025 | |
| Amgen INC. | $24.67 | 2024 | Tepezza |
| Radius Health, INC. | $23.86 | 2025 | Tymlos |
| Amryt Pharma Holdings LTD | $21.28 | 2022 | |
| Esperion Therapeutics, INC. | $20.42 | 2025 | Nexletol |
| Horizon Therapeutics Plc | $20.42 | 2022 | |
| Echosens North America, INC. | $19.38 | 2023 | Fibroscan |
| Medtronic, INC. | $18.19 | 2023 | Minimed 780g |
| Abbott Laboratories | $17.44 | 2019 | |
| Shire North American Group INC | $16.58 | 2019 | |
| Insulet Corporation | $16.46 | 2022 | |
| Mannkind Corporation | $15.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.